Skip to content
10-Q

Quarterly Report

INMED PHARMACEUTICALS INC. INM

0001213900-25-107152

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Oct 31, 2025 2.8M sh
Shares Diluted Q1 2026 · Sep 30, 2025 3.95M sh
Shares Diluted Q1 2026 · Sep 30, 2024 620.13K sh
Operating Cash Flow Q1 2026 · Sep 30, 2025 −$1.61M
Operating Cash Flow Q1 2026 · Sep 30, 2024 −$1.83M
Short Term Investments Q1 2026 · Sep 30, 2025 $42.86K
Short Term Investments Q1 2026 · Jun 30, 2025 $43.38K
Cash And Equivalents Q1 2026 · Sep 30, 2025 $9.33M
Cash And Equivalents Q1 2026 · Jun 30, 2025 $11.08M
Stockholders Equity Q1 2026 · Sep 30, 2025 $11.59M
Stockholders Equity Q1 2026 · Jun 30, 2025 $13.43M
Stockholders Equity Q1 2026 · Sep 30, 2024 $8.4M
Stockholders Equity Q1 2026 · Jun 30, 2024 $9.21M
Current Liabilities Q1 2026 · Sep 30, 2025 $1.55M
Current Liabilities Q1 2026 · Jun 30, 2025 $1.84M
Total Liabilities Q1 2026 · Sep 30, 2025 $1.77M
Total Liabilities Q1 2026 · Jun 30, 2025 $2.15M
Current Assets Q1 2026 · Sep 30, 2025 $10.8M
Current Assets Q1 2026 · Jun 30, 2025 $12.87M
Total Assets Q1 2026 · Sep 30, 2025 $13.36M
Total Assets Q1 2026 · Jun 30, 2025 $15.58M
Eps Diluted Q1 2026 · Sep 30, 2025 −$0.44
Eps Diluted Q1 2026 · Sep 30, 2024 −$2.71
Eps Basic Q1 2026 · Sep 30, 2025 −$0.44
Eps Basic Q1 2026 · Sep 30, 2024 −$2.71
Sga Expense Q1 2026 · Sep 30, 2025 $1.53M
Sga Expense restated Q1 2026 · Sep 30, 2024 $1.49M
Rd Expense Q1 2026 · Sep 30, 2025 $581.61K
Rd Expense restated Q1 2026 · Sep 30, 2024 $700.15K
Net Income Q1 2026 · Sep 30, 2025 −$1.73M
Net Income Q1 2026 · Sep 30, 2024 −$1.68M
Gross Profit Q1 2026 · Sep 30, 2025 $403.16K
Gross Profit Q1 2026 · Sep 30, 2024 $493.41K
Cost Of Revenue Q1 2026 · Sep 30, 2025 $716.96K
Cost Of Revenue Q1 2026 · Sep 30, 2024 $771.23K